MedTrace Logo

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

NCT02612298 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2019-04-17

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension. To provide evidence for hypertension treatment.

A group: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks. B group: Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.

Conditions

  • Essential Hypertension

Interventions

DRUG

Arotinolol Hydrochloride

Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.

DRUG

Metoprolol succinate sustained-release tablet

Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.

Sponsors & Collaborators

  • Sumitomo Pharma (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yundai Chen, MD · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-09-13
Completion
2018-09-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612298 on ClinicalTrials.gov